Ensign Peak Advisors
SYRE icon

Ensign Peak Advisors’s Spyre Therapeutics SYRE Stock Holding History

Ensign Peak Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Sell
126,620
-21,917
-15% -$1.6M 0.02% 414
2026
Q1 		$7.49M Buy
+148,537
New +$5.6M 0.01% 462
2025
Q1 		– Sell
-82,475
Closed -$1.92M – 1725
2024
Q4 		$1.92M Hold
82,475
– – ﹤0.01% 956
2024
Q3 		$2.43M Hold
82,475
– – ﹤0.01% 867
2024
Q2 		$1.94M Buy
+82,475
New +$2.78M ﹤0.01% 923

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ensign Peak Advisors's SYRE Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Spyre Therapeutics (SYRE) stake by 15% in Q2 2026, selling an estimated $1.6M and leaving 126,620 shares worth $11.2M. The position accounts for 0.02% of the portfolio, ranked #414.

Ensign Peak Advisors first reported a position in SYRE in Q2 2024 and has held it in 5 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Ensign Peak Advisors held 126,620 shares of Spyre Therapeutics worth $11.2M as of Q2 2026.
  • Ensign Peak Advisors sold 21,917 Spyre Therapeutics shares in Q2 2026, an estimated $1.6M.
  • Spyre Therapeutics made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #414 holding.
  • Ensign Peak Advisors first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.